O uso de plantas medicinais no tratamento suplementar da Diabetes Mellitus
DOI:
https://doi.org/10.15343/0104-7809.202549e17782025PPalavras-chave:
Fitoterapia, Diabetes Mellitus, Controle Glicêmico, Aloe vera, Ginkgo bilobaResumo
A Diabetes Mellitus (DM) é um distúrbio metabólico crônico de alta prevalência, e o uso de plantas medicinais tem representado uma abordagem complementar promissora para o tratamento dessa condição. Este trabalho teve como objetivo revisar a eficácia de Aloe vera, Curcuma longa e Ginkgo biloba no controle glicêmico e na redução de complicações associadas ao DM. Para isso, foi conduzida uma revisão sistemática seguindo o método PRISMA, utilizando os descritores “Aloe vera”, “Curcuma”, “Ginkgo biloba” e “Diabetes” em bases de dados como PubMed, BVS e SciELO. Foram selecionados artigos publicados entre 2013 e 2024, considerando apenas estudos experimentais e clínicos completos que atendiam aos critérios de inclusão. No total, sete estudos foram incluídos na análise. Os resultados evidenciaram que Aloe vera promoveu reduções significativas na hemoglobina glicada (HbA1c) e na glicemia capilar, mostrando eficácia como adjuvante ao tratamento com metformina. Curcumina em associação com piperina, demonstrou propriedades antioxidantes e anti-inflamatórias, contribuindo também para a redução de HbA1c e glicemia capilar. Por sua vez, Ginkgo biloba apresentou benefícios no controle da glicemia capilar e na prevenção de complicações crônicas, como retinopatia e nefropatia. Embora os fitoterápicos analisados tenham demonstrado potencial terapêutico significativo, os estudos revisados apresentaram limitações metodológicas, como tamanhos amostrais reduzidos e falta de padronização nos protocolos. Apesar disso, Aloe vera, Curcuma longa e Ginkgo biloba mostram-se alternativas promissoras no manejo suplementar do DM, com potencial para reduzir complicações associadas. Contudo, mais estudos de alta qualidade são necessários para consolidar seu uso clínico em protocolos bem definidos.
Downloads
Referências
American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S15–33. https://doi.org/10.2337/dc21-S002
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov 1;157:107843. https://doi.org/10.1016/j.diabres.2019.107843
Pan American Health Organization. Panorama of Diabetes in the Americas [Internet]. 2022 [cited 2023 Nov 20]. Available from: https://iris. paho.org/handle/10665.2/56643
Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004 Jun 1;140(11):945–50. https://doi.org/10.7326/0003-4819-140-11-200406010-0003
Robertson RP. Antagonist: diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. J Lab Clin Med. 1995 May;125(5):560–4; discussion 565.
Lucier J, Weinstock RS. Type 1 Diabetes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Nov 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507713/
Westermark P, Johnson KH, O’Brien TD, Betsholtz C. Islet amyloid polypeptide--a novel controversy in diabetes research. Diabetologia. 1992 Apr;35(4):297–303.
Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004 Nov;27(11):2597–602. https://doi.org/10.2337/diacare.27.11.2597
Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013 May;56(5):965–72. https://doi.org/10.1007/s00125-013- 2841-0
Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001 Mar;50(3):609–13. https://doi.org/10.2337/diabetes.50.3.609
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998 Sep 12;352(9131):854–65. PMID: 9742977
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364–79. https://doi.org/10.2337/dc12-0413
De Carvalho AC, Oliveira AADS, Siqueira LDP. Medicinal plants used in the treatment of Diabetes Mellitus: A review. Braz J Health Rev. 2021 Jun 11;4(3):12873–94. https://doi.org/10.34119/bjhrv4n3-247
Pedroso RDS, Andrade G, Pires RH. Medicinal plants: a perspective on safe and rational use. Physis Rev Saúde Coletiva. 2021;31(2):e310218. https://doi.org/10.1590/S0103-73312021310218
Guimarães BM, Ramos KA, Souza MCD, Franco ML, Alves CCDS, Carli ADP, et al. Therapeutic practices with medicinal plants for the treatment of Diabetes Mellitus. Res Soc Dev. 2021 Aug 16;10(10):e474101018874. https://doi.org/10.33448/rsd-v10i10.18874
Kalluf L de JH. Functional phytotherapy: from active principles to phytotherapic prescriptions. In: Functional phytotherapy [Internet]. 2008 [cited 2023 Nov 26]. p. 304–304. Available from: https://pesquisa.bvsalud.org/portal/resource/pt/lil-558217
Katiyar C, Gupta A, Kanjilal S, Katiyar S. Drug discovery from plant sources: An integrated approach. Ayu. 2012;33(1):10–9. https://doi. org/10.4103/0974-8520.100295
Aziz TA, Hussain SA, Mahwi TO, Ahmed ZA. Efficacy and safety of Ginkgo biloba extract as an “add-on” treatment to metformin for patients with metabolic syndrome: a pilot clinical study. Ther Clin Risk Manag. 2018;1219–26.
Zhao Y, Yu J, Liu J, An X. The Role of Liuwei Dihuang Pills and Ginkgo Leaf Tablets in Treating Diabetic Complications. Evid Based Complement Altern Med. 2016;7931314–7931314.
Aziz TA, Hussain SA, Mahwi TO, Ahmed ZA, Rahman HS, Rasedee A. The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial. Drug Des Devel Ther. 2018;12:735–42.
Devaraj S, Yimam M, Brownell LA, Jialal I, Singh S, Jia Q. Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab Syndr Relat Disord. 2013;35–40. https://doi.org/10.1089/met.2012.0066
Choi HC, Kim SJ, Son KY, Oh BJ, Cho BL. Metabolic effects of aloe vera gel complex in obese prediabetes and early untreated diabetic patients: randomized controlled trial. Nutrition. 2013;1110–4. https://doi.org/10.1016/j.nut.2013.02.015
Alinejad-Mofrad S, Foadoddini M, Saadatjoo SA, Shayesteh M. Improvement of glucose and lipid profile status with Aloe vera in pre-diabetic subjects: a randomized controlled-trial. J Diabetes Metab Disord. 2015;22–22. https://doi.org/10.1186/s40200-015-0137-2
Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomedicine. 2016;6(5):567–77.
Adab Z, Eghtesadi S, Vafa M, Heydari I, Shojaii A, Haqqani H, et al. Effect of turmeric on glycemic status, lipid profile, hs‐CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytother Res. 2019 Apr;33(4):1173–81.
Sukandar EY, Sudjana P, Adnyana IK, Setiawan AS, Yuniarni U. Recent Study of Turmeric in Combination with Garlic as Antidiabetic Agent. Procedia Chem. 2014;13:44–56.
Panahi Y, Khalili N, Sahebi E, Namazi S, Simental-Mendía L, Majeed M, et al. Effects of Curcuminoids Plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo-Controlled Trial. Drug Res. 2018 Jul;68(7):403–9.
Fleming T, editor. PDR for herbal medicines. 2nd ed. Montvale, NJ: Medical Economics Co; 2000. https://naturalingredient.org/wp/wp content/uploads/Pdr_for_Herbal_Medicines.pdf
Eshun K, He Q. Aloe vera: a valuable ingredient for the food, pharmaceutical and cosmetic industries--a review. Crit Rev Food Sci Nutr. 2004;44(2):91–6. https://doi.org/10.1080/10408690490424694
PubChem. CID 369012 [Internet]. [cited 2024 Jan 4]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/369012
Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus. Phytomedicine Int J Phytother Phytopharm. 1996 Nov;3(3):241–3.
Pejuçara Aloe Use - RS | Journal of Health Sciences [Internet]. [cited 2023 Dec 2]. Available from: https://journalhealthscience.pgsskroton. com.br/article/view/301
Queiroga V de P. Aloe vera (babosa): commercial scale planting technologies for the semi-arid region and utilization. Arepb; 2018. https:// www.infoteca.cnptia.embrapa.br/infoteca/handle/doc/1120076
Tseng-Crank J, Do SG, Corneliusen B, Hertel C, Homan J, Yimam M, et al. UP780, a Chromone-Enriched Aloe Composition, Enhances Adipose Insulin Receptor Signaling and Decreases Liver Lipid Biosynthesis. Open J Genet. 2013 Jul 21;3(2):9. https://doi.org/10.4236/ojgen.2013.32A2002
Yimam M, Zhao J, Corneliusen B, Pantier M, Brownell L, Jia Q. Blood glucose-lowering activity of aloe-based composition, UP780, in alloxan induced insulin-dependent mouse diabetes model. Diabetol Metab Syndr. 2014 May 24;6:61. https://doi.org/10.1186/1758-5996-6-61
Shin S, Kim S, Oh HE, Kong H, Shin E, Do SG, et al. Dietary Aloe QDM Complex Reduces Obesity-Induced Insulin Resistance and Adipogenesis in Obese Mice Fed a High-Fat Diet. Immune Netw. 2012 Jun;12(3):96–103. https://doi.org/10.4110/in.2012.12.3.96
Lee Y, Kim J, An J, Lee H, Kong H, Song Y, et al. Aloe QDM complex enhances specific cytotoxic T lymphocyte killing in vivo in metabolic disease mice. Biosci Biotechnol Biochem. 2017 Mar 4;81(3):595–603. https://doi.org/10.1080/09168451.2016.1258986
Shin E, Shin S, Kong H, Lee S, Do SG, Jo TH, et al. Dietary Aloe Reduces Adipogenesis via the Activation of AMPK and Suppresses Obesity-related Inflammation in Obese Mice. Immune Netw. 2011;11(2):107.
G PTF, A EMRu, M TS, R GA. The effectiveness and safety of Aloe vera as an adjunct treatment to metformin in diabetic patients seen at the QCGH family medicine outpatient department. Filip Fam Physician. 2015;25–35.
Borg MJ, Rayner CK, Jones KL, Horowitz M, Xie C, Wu T. Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin. Pharmaceuticals. 2020 Nov 22;13(11):410.
McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016 Mar;59(3):426–35.
Raju B, Resta C, Tibaldi JT. Metformin and late gastrointestinal complications. Am J Med. 2000 Aug;109(3):260–1. doi:10.1016/S0002- 9343(00)00522-2
Seliprandy Peres A, Garonci Alves Vargas E, Rocha Simonin De Souza V. Functional Properties of Turmeric in Nutritional Supplementation. REINPEC. 2015 Dec 10;1(2):218–29.
Alonso J. Tratado de fitofármacos e nutracêuticos. AC Farmacêutica; 2013.
Avci G, Kadioglu H, Sehirli AO, Bozkurt S, Guclu O, Arslan E, et al. Curcumin protects against ischemia/reperfusion injury in rat skeletal muscle. J Surg Res. 2012 Jan;172(1):e39–46.
Sabir SM, Zeb A, Mahmood M, Abbas SR, Ahmad Z, Iqbal N. Phytochemical analysis and biological activities of ethanolic extract of Curcuma longa rhizome. Braz J Biol. 2020 Sep 21;81:737–40.
Silva JM da, Silva VG da, Araujo RR da S, Araujo MCC de, Constant PBL, Fanchiotti FE. Properties of Curcuma longa L. in type 2 diabetes mellitus: Integrative review. RBONE - Rev Bras Obesidade Nutr E Emagrecimento. 2020;14(90):1180–91.
Priyadarsini KI. The Chemistry of Curcumin: From Extraction to Therapeutic Agent. Molecules. 2014 Dec 1;19(12):20091–112.
Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial. Diabetol Metab Syndr. 2019 Dec;11(1):41.
Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res. 2013 Sep;57(9):1569–77.
Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem. 2014 Feb;25(2):144–50.
Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high fat-fed hamsters. Metabolism. 2008 Nov;57(11):1576–83.
Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008 Jul;149(7):3549–58.
Biernacka P, Adamska I, Felisiak K. The Potential of Ginkgo biloba as a Source of Biologically Active Compounds—A Review of the Recent Literature and Patents. Molecules. 2023 May 9;28(10):3993.
Drieu K. Preparation and Definition of Ginkgo biloba Extract. In: Fünfgeld EW, editor. Rökan. Berlin, Heidelberg: Springer; 1988. p. 32–6.
Cheng D, Liang B, Li Y. Antihyperglycemic Effect of Ginkgo biloba Extract in Streptozotocin-Induced Diabetes in Rats. BioMed Res Int. 2013;2013:162724.
Kudolo GB, Bressler P, DeFronzo RA. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J Lipid Mediat Cell Signal. 1997 Nov;17(2):97–113.
Robertson RP, Tanaka Y, Takahashi H, Tran POT, Harmon JS. Prevention of oxidative stress by adenoviral overexpression of glutathione-related enzymes in pancreatic islets. Ann N Y Acad Sci. 2005 Jun;1043:513–20.
Ajabnoor MA. Effect of aloes on blood glucose levels in normal and alloxan diabetic mice. J Ethnopharmacol. 1990 Feb;28(2):215–20.
Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol. 2001 Jun;41(6):600–11.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2025 O Mundo da Saúde
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
.jpg)
